The American Society of Hematology (ASH) recently announced the election of three new members to its Executive Committee for terms beginning after the ASH Annual Meeting in December. Charles S. Abrams, MD, will serve a 1-year term as Vice President, followed by successive terms as President-Elect and President. Michelle Le Beau, PhD, and Martin Tallman, MD, will both serve 4-year terms as Councillor.
Great Discoveries in the Midst of Challenges
“This is an exciting yet challenging time for the field,” said 2013 ASH President Janis L. Abkowitz, MD, of the University of Washington. “While we are poised to make great discoveries, we are also faced with the continual threat of decreased federal research funding and significant changes in the health-care system that allows us to deliver care to our patients. Navigating these opportunities and challenges requires strong, visionary leaders like Drs. Abrams, Le Beau, and Tallman.”
New Members to ASH Executive Committee
Charles S. Abrams, MD, is Director of the University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia Blood Center for Patient Care & Discovery and Associate Chief of Hematology/Oncology at the University of Pennsylvania. His major fields of interest include phosphoinositide signaling in hematopoietic cells, platelet adhesion and thrombosis, and murine models of hemostasis. Outside of the laboratory, Dr. Abrams is interested in mentoring young hematologists and developing continuing medical education programs in clinical hematology. Dr. Abrams previously served a 4-year term as ASH Secretary from 2009 to 2012.
Michelle Le Beau, PhD, is Director of University of Chicago Comprehensive Cancer Center and the University of Chicago Cancer Cytogenetics Laboratory and the Arthur and Marian Edelstein Professor of Hematology/Oncology at the University of Chicago. Her major research interests include cancer cytogenetics and genetics, genetic pathways that lead to myelodysplastic syndromes, acute myeloid leukemia, and therapy-related myeloid neoplasms.
Martin S. Tallman, MD, is Chief of the Leukemia Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York. He also served as Chair of the Leukemia Committee of the Eastern Cooperative Oncology Group for 16 years. Dr. Tallman’s fields of interest include clinical investigation in acute myeloid and acute lymphocytic leukemia, acute promyelocytic leukemia, and hairy cell leukemia. ■